Feb 4 (Reuters) - Merck & Co Inc MRK.N:
Q4 ADJUSTED EPS $1.72 VERSUS IBES ESTIMATE $1.62
OUTLOOK 2025 ADJUSTED EPS $8.88 - $9.03 VERSUS IBES ESTIMATE $9.02
OUTLOOK 2025 WORLDWIDE SALES $64.1 BILLION - $65.6 BILLION VERSUS IBES ESTIMATE $67.31 BILLION
2025 SALES RANGE REFLECTS DECISION TO TEMPORARILY PAUSE SHIPMENTS OF GARDASIL/GARDASIL 9 TO CHINA FROM FEB THROUGH AT LEAST MID-YEAR
Q4 WORLDWIDE SALES $15.62 BILLION VERSUS IBES ESTIMATE $15.49 BILLION
Q4 KEYTRUDA SALES $7.84 BILLION
Q4 GARDASIL/GARDASIL 9 SALES $1.55 BILLION, DOWN 17% DUE TO LOWER DEMAND IN CHINA
Source text: [ID:]
Further company coverage: MRK.N